A logo Agilent Technologies +
Agilent Technologies
+

Agilent Technologies (A) Business News

Track Agilent Technologies in real time with a live news feed covering Agilent Technologies stock news, official press releases, company announcements, and an archive of historical Agilent Technologies news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

Business Wire

8:00 AM | Wednesday | Jul 29, 2026

news photo
Loading...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

Read full article redirect
8:00 AM | Wednesday | Jul 29, 2026

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea.

Read full article arrow
News Thumbnail
4:15 PM | Tuesday | Jul 28, 2026

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.
m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo.

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Jul 23, 2026

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD.

Read full article arrow
News Thumbnail
3:11 AM | Monday | Jul 20, 2026

Agilent Increases Its Investment in HALO X-ray Technologies

Business Wire

NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Jul 14, 2026

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb'.

Read full article arrow
News Thumbnail
8:00 AM | Wednesday | Jul 8, 2026

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides.

Read full article arrow
News Thumbnail
8:00 AM | Wednesday | Jul 1, 2026

Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to.

Read full article arrow
News Thumbnail
8:06 AM | Thursday | Jun 25, 2026

Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies

GlobeNewsWire

Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ("Agilent", NYSE:A).

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Jun 25, 2026

Agilent Completes Acquisition of Biocare Medical

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent's Life Sciences and Diagnostics Markets Group.“We are pleased to complete our acquisition of Biocare, which represents a natural and st.

Read full article arrow
News Thumbnail
10:09 AM | Wednesday | Jun 24, 2026

Lost Money on Verra Mobility Corporation (VRRM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

PRNewsWire

Alert: Claims Focus on Alleged Misrepresentations About the Durability of Verra Mobility's Largest Customer Contract and the $35 Million Revenue Hole Left by Avis Budget Group's Termination NEW YORK, June 24, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Verra Mobility Corporation (NASDAQ: VRRM) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased VRRM securities between February 24, 2026 and May 26, 2026.

Read full article arrow
News Thumbnail